NCT05017142 Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
| NCT ID | NCT05017142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bern |
| Condition | Optic Neuritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2020-04-14 |
| Primary Completion | 2071-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2020-04-14 with a primary completion date of 2071-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland opened for recruitment after that: Aarau, Basel, Bellinzona, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur and Zurich. The center in Fribourg is expected open for recruitment in 2025. The registry provides data for national and international monitoring and research. It supports research on inflammatory brain diseases in Switzerland and the exchange of knowledge between clinicians, researchers, and therapists. The registry aims to improve the treatment of children with inflammatory brain diseases and optimizing their health care and quality of life.
Eligibility Criteria
Inclusion Criteria: All patients living and/or treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18. * Written informed consent by patients (and/or legal representative(s), if applicable) * Optic Neuritis * Transverse Myelitis * Acute disseminated encephalomyelitis * Multiple Sclerosis * Neuromyelitis Optica Spectrum Disorders * Myelin oligodendrocyte glycoprotein antibody-associated disease * Anti-NMDA-R Encephalitis * Anti-GAD65 Associated Autoimmune Encephalitis * Anti-AMPAR-1/2 Associated Autoimmune Encephalitis * Anti-Lgi-1 Associated Autoimmune Encephalitis * Anti-CASPR-2 Associated Autoimmune Encephalitis * Anti-GABAR-1/2 Associated Autoimmune Encephalitis * Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis * Hashimoto Encephalopathy * CNS Vasculitis * CNS Sarcoidosis * CNS Lupus * Rasmussen Encephalitis Exclusion Criteria: * Neurological symptoms due to infectious diseases of the CNS * Genetic/metabolic causes of central demyelinating diseases * Neurological symptoms due to Guillain-Barré-Syndrome
Contact & Investigator
Sandra Bigi, PD MD
PRINCIPAL INVESTIGATOR
ISPM, University of Bern, Bern; Kinderspital Zentralschweiz, Luzern
Frequently Asked Questions
Who can join the NCT05017142 clinical trial?
This trial is open to participants of all sexes, up to 36 Years, studying Optic Neuritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05017142 currently recruiting?
Yes, NCT05017142 is actively recruiting participants. Contact the research team at lorena.hulliger@unibe.ch for enrollment information.
Where is the NCT05017142 trial being conducted?
This trial is being conducted at Aarau, Switzerland, Sankt Gallen, Switzerland, Lausanne, Switzerland, Winterthur, Switzerland and 9 additional locations.
Who is sponsoring the NCT05017142 clinical trial?
NCT05017142 is sponsored by University of Bern. The principal investigator is Sandra Bigi, PD MD at ISPM, University of Bern, Bern; Kinderspital Zentralschweiz, Luzern. The trial plans to enroll 500 participants.